Events/News

Claremont Creek Ventures portfolio company Shotspotter was featured in the Washington Post

By Randy Hawks / November 4, 2013 / 0 Comments

It’s very cool that our portfolio company ShotSpotter was just profiled in the Washington Post (ShotSpotter detection system documents 39,000 shooting incidents in the District). In Washington DC, ShotSpotter has 300 acoustic sensors across 20 square miles of the city, covering mainly the Southeast and Northeast of the District. ShotSpotter is a unique gunfire surveillance […]

Read More

Assurex Health Publishes Seminal Paper on Pharmacogenomics

By Brad Webb / November 2, 2013 / 0 Comments

Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry. The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing […]

Read More

Genalyte Receives National Cancer Institute Grant

By Brad Webb / October 21, 2013 / 0 Comments

Our portfolio company Genalyte just announced the award of a government grant from the National Cancer Institute for the development of a  diagnostic system using Genalyte’s proprietary biomarker technology (see Genalyte Expands into Cancer Profiling with $1 Million NCI Grant to Develop Cancer Biomarker Panel). This project is a significant validation of the company’s capability […]

Read More

Alphabet Energy and Clean Power Finance honored at Global Cleantech 100 Gala

By Paul Straub / October 10, 2013 / 0 Comments

The Global Cleantech 100 Gala honored and celebrated the achievements of the 2013 Global Cleantech 100 companies, the 100 top innovators in cleantech today.

Two of Claremont Creek Ventures portfolio companies, Alphabet Energy and Clean Power Finance were named to the list to the top 100 Global Cleantech companies.

Read More

Numedii discovers repurposed antidepressants have potential to treat small cell lung cancer

By Ted Driscoll / September 28, 2013 / 0 Comments

Congratulations to our portfolio company NuMedii for a publication today in Cancer Discovery, which discusses the use of its technology by Stanford researchers to identify an antidepressant as a potential treatment for small cell lung cancer. NuMedii is a pioneer in the future of pharmacology. As medicine becomes more personalized, every individual will get a […]

Read More

Assurex Health Appoints Veteran P&G Consumer Products Executive Virginia Coleman Drosos President to Lead Personalized Medicine Growth

By Claremont Creek Alerts / September 12, 2013 / 0 Comments

Congratulations to our portfolio company Assurex Health which appointed Consumer Products Executive Virginia Coleman Drosos President to Lead the company. We are so excited to have her in this position and wish her all the best.

Read More

Meet our team

Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.

Nat_Boldhaber7718 -1200px

NAT GOLDHABER

Nat Goldhaber is a co-founder of Claremont Creek Ventures. 

Brad_Webb8124 1200px crop

BRAD WEBB

Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.

Randy_Hawks7690 -1200px

RANDY HAWKS

Randy Hawks is a co-founder of Claremont Creek Ventures.

Post Categories

Archives